All News
#ACR21 Abst#0916
⭐️AxSpa pts in remission: Full Certolizumab vs 1/2 dose vs PBO
▶️ 85% w/o flare in full dose, 80% in 1/2 dose, just 23% in PBO
▶️ PBO pts with NO flare STILL showed ⬆️ ASDAS, BASDAI, and CRP
🔥Would ⬇️ not d/c Cimzia!
@Rheumnow https://t.co/uc5JDVY0ud #ACRBest https://t.co/fOssPlTEwR
Links:
Eric Dein ericdeinmd ( View Tweet)
We are live! Join us!
RheumNow Daily Recap - #ACR21 https://t.co/hUqx6B2ySD via @YouTube
Links:
Dr. John Cush RheumNow ( View Tweet)
Small numbers but mirrors data from TENOR and plenty to think about here. We clearly want to see sustained remission and Ax details, but very promising!
Definitely on the agenda for the @RheumNow #ACR21 GCA/PMR panel on Wed am with @LCalabreseDO @Sarah_L_Mackie @RichardPAConway
David Liew drdavidliew ( View Tweet)
@benjaminsutu @RheumNow Always steroids first, we learned that the hard way in GUSTO - but yeah, probably something after that, and TCZ is our only b/tsDMARD choice... for the time being
(at #ACR21 - mavrilimumab, baricitinib, secukinumab...)
David Liew drdavidliew ( View Tweet)
Dr. Petri noted that 1 week off of immunosuppressants is adequate for most lupus patients to mount a response. She avoided RTX during the pandemic. In pts who have had inadequate response to 2 or 3 doses of mRNA, she switches them to J&J. #ACR21 #COVI19 CH @rheumnow https://t.co/qNjmx9uTLF
TheDaoIndex KDAO2011 ( View Tweet)
TNFi + JIA = watch the skin! A nearly 3fold increase of paradoxal psoriasis in JIA patients exposed to TNFi reported in the CARRA registry w/ incidence rate the highest on children receiving adalimumab.
#Abst0241 @RheumNow #ACR2021 https://t.co/uXOwV2RlGu https://t.co/8f8mvVUkV2
Aurelie Najm AurelieRheumo ( View Tweet)
Treatment for VEXAS syndrome. It is steroid responsive. Avoid IL-1 inhibitors severe skin reactions at injection site, bone marrow transplant may be curative @RheumNow #ACR21 Session6S410 L Wilson, DO Cordona https://t.co/eQ1KVDiKKV
Dr. Antoni Chan synovialjoints ( View Tweet)
HSS Study of 136 SLE flares post-vax:
👉100 (74%) w/expected AE (headache/myalgias)
👉11 (8.1%) pts with SLE flare
👉Majority of flares were mild-mod & occurred w/in 1 week of vaccination
👉Most resolved w/in 7 days.
Abst#0896 #ACR21 @rheumnow
https://t.co/e6AP8PPRH2
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Katie Liao presented an observational study comparing SLE pts who were Ro neg (n=208) vs Ro pos (n=185).
More of the (+)Ro pts had:
⬆️Adjusted mean SLEDIA >4
⬆️Proteinuria
⬆️Neutropenia,+RF, +dsDNA, and low C3 or C4
⬆️Discoid or malar rash
#ACR21 Abst#0323 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Fatigue fills us with dread: common, big issue, no proven meds, non-pharm Rx hard to access.
Pragmatic RCT in UK, inflamm rheum dx:
usual care v CBT v exercise program
(all remote delivery)
Clinically meaningful benefit - now how to access?
LIFT study #ACR21 ABST0462 @RheumNow https://t.co/XsSCzkbcCd
David Liew drdavidliew ( View Tweet)
@JointMD shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. @RheumNow #acr21 https://t.co/mVw05iFPhF
TheDaoIndex KDAO2011 ( View Tweet)
Rheumatologists and Health Professionals: Join us tonight for RheumNow's #ACR21 Daily Recap at 7pm Eastern time . Register via the Zoom link below.
https://t.co/MalO30jgo1
Or visit our YouTube channel-RheumNow.
https://t.co/nBUk64XBjU https://t.co/pYEFOM1Q2g
Dr. John Cush RheumNow ( View Tweet)
Distinguishing between #preeclampsia and #lupus nephritis flare in 🤰 #SLE patients is very important because management is different. #rheumatology #medtwitter https://t.co/Dc9ohJQ75L
sheila RHEUMarampa ( View Tweet)
Blurred line btwn RA, preRA & RA prevention which makes interpretation of RCTs problematic. I’ve learned that if pt has RA not meeting criteria, some Rx ⬇️chance of RA over time-MTX, now #Abatacept but was it RA anyway AND what happens when you stop Rx? #ACR21 @RheumNow abst#0505 https://t.co/HwivsITvCQ
Janet Pope Janetbirdope ( View Tweet)
#ACR21 #Aging #CommunityHub @UnaMakris @SattuiSEMD @KWyshamMD
Very engaging discussion on the 5 Ms of aging + how they interconnect:
👉🏻multimorbidity (⬆️ risk)
👉🏻meds (poly pharmacy)
👉🏻mentation (cognitive impairment)
👉🏻mobility and disability
👉🏻what matters most <to patient> https://t.co/mZpk3qQFgz
Elena MyasoedovaMD MyasoedovaElena ( View Tweet)
#ACR21 #Abstr0437 OK, so RTX affects #COVID vaccine but some pts need RTX. Factors predicting response to vaccine:
RA vs AAV/IIM
Higher IgG
Longer time-to-RTX
Lower RTX courses Number.
Prediction Calculator is developed but need ext. validation #RheumNow https://t.co/iXSaGQ76hS https://t.co/WQAV3GRPBz
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr0336 ANA is not a great test for #lupus diagnosis. Multianalyte Assay Panel with Cell-Bound Complement Activation Products could improve diagnosis (OR 6.3) and Drug Initiation (OR 2.8). Can we speed up implementation to clinic? #RheumNow https://t.co/jLcAtD7FaY https://t.co/YmLwmVWp6k
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr0261 In stable Non sJIA, is it safe to taper or stop MTX? Of 375 pts in CARRA registry, 24% tapered and 14% stopped MTX. No diff in flare rates btw those continued vs tapered/stopped. Sustained remission was in ⬆️tapered vs stopped @RheumNow https://t.co/Mm1yfzRBQz https://t.co/rkHvXWj2oO
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The #Lupus Faculty @RheumNow is proud to share our latest video about learning points from a jam-packed day at #ACR21 https://t.co/LRyuYyHlhi @KDAO2011 @Janetbirdope @bella_mehta @_Castillo_Pedro
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 Ignaki Sanz makes the case that +++ AUTOANTIBODIES are integrally involved in #COVID19 immunopathogeneisis and may rise and fall w disease states- TBD what role they play in acute disease and #LongCovid @CCalabreseDO @VirusesImmunity @CleClinicMD #COVID19AB https://t.co/9dzCSh5V7R
Leonard Calabrese LCalabreseDO ( View Tweet)